Metronidazole
Rank #440 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$18.0M
Total Cost
405,967
Total Claims
$18.0M
Total Cost
17,762
Prescribers
$44
Cost per Claim
241,007
Beneficiaries
430,858
30-Day Fills
$1,015
Avg Cost/Provider
23
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$18.0M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $18.0M total
Top Prescribers of Metronidazole
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Lyudmila Magakyan-Martinez | Nurse Practitioner | New York, NY | 622 | $59K |
| 2 | Navid Ezra | Dermatology | Thousand Oaks, CA | 365 | $41K |
| 3 | Pamela Leve | Dermatology | Rochester, NY | 469 | $32K |
| 4 | Joshua Shapiro | Physician Assistant | New York, NY | 394 | $31K |
| 5 | Liliya Besedina | Dermatology | Bayonne, NJ | 254 | $27K |
| 6 | Karina Torres | Nurse Practitioner | Miami, FL | 252 | $25K |
| 7 | Bijan Setareh-Shenas | Dermatology | Plainview, NY | 305 | $24K |
| 8 | Roman Bronfenbrener | Micrographic Dermatologic Surgery | Southampton, PA | 328 | $23K |
| 9 | Edith Winter | Dermatology | Raleigh, NC | 399 | $22K |
| 10 | Huachen Wei | Dermatology | Elmhurst, NY | 228 | $22K |
| 11 | Jennifer Gray | Dermatology | Old Saybrook, CT | 234 | $21K |
| 12 | Athena Phan | Dermatology | Montgomery, AL | 231 | $20K |
| 13 | Anthony Perri | Dermatology | Conroe, TX | 252 | $20K |
| 14 | Anthony Flood | Family Practice | Washington, DC | 186 | $19K |
| 15 | Pinkas Lebovits | Dermatology | New York, NY | 242 | $18K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 437 | Sacrosidase (Sucraid) | $18.5M | 1,517 |
| 438 | Enasidenib Mesylate (Idhifa) | $18.1M | 554 |
| 439 | Posaconazole (Posaconazole) | $18.0M | 7,163 |
| 440 | Metronidazole (Metronidazole) | $18.0M | 405,967 |
| 441 | Rufinamide (Rufinamide) | $18.0M | 8,793 |
| 442 | Istradefylline (Nourianz) | $17.8M | 7,061 |
| 443 | Encorafenib (Braftovi) | $17.6M | 1,209 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology